Last reviewed · How we verify
NCT06612788
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)
NA trial testing Exablate Model 4000 Type 2.0/2.1 in Opioid Use Disorder in 5 participants. Completed in 25 April 2025.
8 July 2024
Quick facts
| Lead sponsor | West Virginia University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 19 September 2023 |
| Primary completion | 8 July 2024 |
| Estimated completion | 25 April 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Exablate Model 4000 Type 2.0/2.1
Conditions studied
- Opioid Use Disorder — all drugs for Opioid Use Disorder →
Sponsor
West Virginia University
Who can join
Adults 18 to 60, any sex, with Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) by assessing its safety and tolerability in subjects with OUD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06612788
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exablate Model 4000 Type 2.0/2.1
Trials testing the same drug.
- NCT04197921 — Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs) · NA · recruiting
Other recruiting trials for Opioid Use Disorder
Currently open trials in the same condition.
- NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
- NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
- NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
- NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
- NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting
Other West Virginia University trials
Trials by the same sponsor.
- NCT06686914 — The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex · Phase 1 · recruiting
- NCT06791850 — Sustaining Home Heart Failure Palliative Care in Rural Appalachia · NA · recruiting
- NCT05705999 — Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study · NA · recruiting
- NCT05353244 — Effects of PrTMS on Performance · NA · withdrawn
- NCT05977868 — Comparing Oral Versus Parenteral Antimicrobial Therapy · Phase 4 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06612788 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West Virginia University
- Last refreshed: 20 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06612788.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing